SLC5A2 and diabetes mellitus: Across the four CVOTs described above, beneficial effects of the SGLT2 inhibitor on the various renal parameters were evident (to a greater or lesser extent) irrespective of gender, ethnicity, age, weight, duration or severity of diabetes; presence or absence of cardiovascular disease; and baseline eGFR or baseline albuminuria.